Korean J Physiol Pharmacol.  2021 Sep;25(5):439-448. 10.4196/kjpp.2021.25.5.439.

Anti-inflammatory effects of DA-9601, an extract of Artemisia asiatica, on aceclofenac-induced acute enteritis

Affiliations
  • 1Department of Pharmacology, College of Medicine, Dankook University, Cheonan 31116, Korea.
  • 2Research Institute of Dong-A ST Co., Ltd., Yongin 17073, Korea.
  • 3Department of Biochemistry, College of Medicine, Chung-Ang University, Seoul 06974, Korea.
  • 4Department of Pathology, College of Medicine, Dankook University, Cheonan 31116, Korea.
  • 5NeuroVis Inc., Cheonan 31035, Korea.

Abstract

DA-9601 is an extract obtained from Artemisia asiatica, which has been reported to have anti-inflammatory effects on gastrointestinal lesions; however, its possible anti-inflammatory effects on the small intestine have not been studied yet. Therefore, in this study, we investigated the protective effects of DA-9601 against the ACF-induced small intestinal inflammation. Inflammation of the small intestine was confirmed by histological studies and the changes in the CD4 + T cell fraction induced by the inflammation-related cytokines, and the inflammatory reactions were analyzed. Multifocal discrete small necrotic ulcers with intervening normal mucosa were frequently observed after treatment with ACF. The expression of IL-6, IL-17, and TNF-α genes was increased in the ACF group; however, it was found to have been significantly decreased in the DA-9601 treated group. In addition, DA-9601 significantly decreased the levels of proinflammatory mediators such as IL-1β, GMCSF, IFN-γ, and TNF-α; the anti-inflammatory cytokine IL-10, on the other hand, was observed to have increased. It is known that inflammatory mediators related to T cell imbalance and dysfunction continuously activate the inflammatory response, causing chronic tissue damage. The fractions of IFN-γ + Th1 cells, IL-4 + Th2 cells, IL-9 + Th9 cells, IL-17 + Th17 cells, and Foxp3 + Treg cells were significantly decreased upon DA-9601 treatment. These data suggest that the inflammatory response induced by ACF is reduced by DA-9601 via lowering of the expression of genes encoding the inflammatory cytokines and the concentration of inflammatory mediators. Furthermore, DA-9601 inhibited the acute inflammatory response mediated by T cells, resulting in an improvement in ACF-induced enteritis.

Keyword

DA-9601; Inflammation; NSAIDs; Small intestine; T cell

Figure

  • Fig. 1 Representative images depicting histological appearance of small intestine tissues after ACF-induced enteropathy. (A) Small intestine section from the normal control group. Small intestine section from (B) ACF treated group (C) ACF + DA-9601 treated group, (D) ACF + ESO treated group, and (E) ACF + ESO + DA-9601 treated group. Multifocal discrete small necrotic ulcers with intervening normal mucosa were observed. Frequent necrotic ulcers through small intestine were also observed, and the degrees of necrotic damage were considered very severe with accompanying intestinal micro perforations with peritonitis (H&E, magnification: ×40 and ×100). ACF, aceclofenac; ESO, esomeprazole.

  • Fig. 2 Expression levels of IL-6, IL-17, and TNF-α mRNA in small intestine after ACF-induced enteropathy. Expression of IL-6 (A), IL-17 (B), and TNF-α (C) was quantified using qRT-PCR. The relative mRNA levels of IL-6, IL-17, and TNF-α were calculated by normalizing them to the expression level of GAPDH by using the 2–∆∆Ct method. The expression values obtained from the drug-treated small intestine were normalized to those of the control. Data are represented as the mean ± SEM. A, aceclofenac (ACF); D, DA-9601; E esomeprazole. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

  • Fig. 3 Concentrations of IL-6, IL-1β, IL-10, GM-CSF, IFN-γ, and TNF-α in small intestine after ACF-induced enteropathy. Quantification of (A) IL-6, (B) IL-10, (C) IL-1β, (D) GM-CSF, (E) IFN-γ, and (F) TNF-α in the small intestine by using ELISA. The concentration of whole lysates homogenized from each sample was normalized, and the lysates were diluted within the measurable range. Statistical significance was evaluated using one-way ANOVA. Data are represented as mean ± SEM. A, aceclofenac (ACF); D, DA-9601; E, esomeprazole. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

  • Fig. 4 Flow cytometric characteristics of CD4+T cells in small intestine after ACF-induced enteropathy. (A) Numbers inside quadrant indicate the percentage of the cell population. Only 30% of the cell populations were presented in the flow cytometric characteristics graph. (B) The proportion of CD4+ T cells from lamina propria was determined according to intracellular levels of cytokines for (a) interferon (IFN)-γ+ Th1 cell, (b) interleukin (IL)-4+ Th2 cells, (c) IL-9+ Th9 cells, (d) IL-17+ Th17 cells, and (e) Foxp3+ Treg cells. A, aceclofenac (ACF); D, DA-9601; E, esomeprazole.


Reference

1. M'Koma AE. 2013; Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 6:33–47. DOI: 10.4137/CGast.S12731. PMID: 24833941. PMCID: PMC4020403.
2. Podolsky DK. 2002; Inflammatory bowel disease. N Engl J Med. 347:417–429. DOI: 10.1056/NEJMra020831. PMID: 12167685.
Article
3. Jo-Watanabe A, Okuno T, Yokomizo T. 2019; The role of leukotrienes as potential therapeutic targets in allergic disorders. Int J Mol Sci. 20:3580. DOI: 10.3390/ijms20143580. PMID: 31336653. PMCID: PMC6679143.
Article
4. Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fuchs CS, Chan AT. 2012; Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 156:350–359. DOI: 10.7326/0003-4819-156-5-201203060-00007. PMID: 22393130. PMCID: PMC3369539.
5. Laine L, Smith R, Min K, Chen C, Dubois RW. 2006; Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 24:751–767. DOI: 10.1111/j.1365-2036.2006.03043.x. PMID: 16918879.
Article
6. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. 2011; Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 141:1314–1322. 1322.e1-e5. DOI: 10.1053/j.gastro.2011.06.075. PMID: 21745447.
Article
7. Satoh H, Amagase K, Takeuchi K. 2012; Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther. 343:270–277. DOI: 10.1124/jpet.112.197475. PMID: 22854201.
Article
8. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. 2009; Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 104:1633–1641. DOI: 10.1038/ajg.2009.164. PMID: 19574968.
Article
9. Legrand E. 2004; Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 5:1347–1357. DOI: 10.1517/14656566.5.6.1347. PMID: 15163279.
Article
10. Lee OY, Kang DH, Lee DH, Chung IK, Jang JY, Kim JI, Cho JW, Rew JS, Lee KM, Kim KO, Choi MG, Lee SW, Lee ST, Kim TO, Shin YW, Seol SY. 2014; A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment. Arch Pharm Res. 37:1308–1316. DOI: 10.1007/s12272-014-0408-3. PMID: 24871787. PMCID: PMC4176566.
Article
11. Huh K, Kwon TH, Shin US, Kim WB, Ahn BO, Oh TY, Kim JA. 2003; Inhibitory effects of DA-9601 on ethanol-induced gastrohemorrhagic lesions and gastric xanthine oxidase activity in rats. J Ethnopharmacol. 88:269–273. DOI: 10.1016/S0378-8741(03)00235-6. PMID: 12963154.
Article
12. Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Cho SW, Lee KM, Hahm KB. 2001; Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut. 49:364–371. DOI: 10.1136/gut.49.3.364. PMID: 11511558. PMCID: PMC1728432.
Article
13. Boynton CS, Dick CF, Mayor GH. 1988; NSAIDs: an overview. J Clin Pharmacol. 28:512–517. DOI: 10.1002/j.1552-4604.1988.tb03170.x. PMID: 3047176.
Article
14. Scheiman JM. 2013; The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 15(Suppl 3):S5. DOI: 10.1186/ar4177. PMID: 24267413. PMCID: PMC3891010.
Article
15. Tai FWD, McAlindon ME. 2018; NSAIDs and the small bowel. Curr Opin Gastroenterol. 34:175–182. DOI: 10.1097/MOG.0000000000000427. PMID: 29438118.
Article
16. Park SC, Chun HJ, Kang CD, Sul D. 2011; Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol. 17:4647–4653. DOI: 10.3748/wjg.v17.i42.4647. PMID: 22180706. PMCID: PMC3237301.
Article
17. Oh TY, Ryu BK, Ko JI, Ahn BO, Kim SH, Kim WB, Lee EB, Jin JH, Hahm KB. 1997; Protective effect of DA-9601, an extract of Artemisiae Herba, against naproxen-induced gastric damage in arthritic rats. Arch Pharm Res. 20:414–419. DOI: 10.1007/BF02973932. PMID: 18982482.
18. Kim HS, Kundu JK, Lee JS, Oh TY, Na HK, Surh YJ. 2008; Chemopreventive effects of the standardized extract (DA-9601) of Artemisia asiatica on azoxymethane-initiated and dextran sulfate sodium-promoted mouse colon carcinogenesis. Nutr Cancer. 60 Suppl 1:90–97. DOI: 10.1080/01635580802404170. PMID: 19003585.
19. Laine L. 1996; Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am. 6:489–504. DOI: 10.1016/S1052-5157(18)30351-9. PMID: 8803564.
Article
20. Blackler RW, Gemici B, Manko A, Wallace JL. 2014; NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol. 19:11–16. DOI: 10.1016/j.coph.2014.05.008. PMID: 24929967.
Article
21. Gwee KA, Goh V, Lima G, Setia S. 2018; Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 11:361–374. DOI: 10.2147/JPR.S156938. PMID: 29491719. PMCID: PMC5817415.
Article
22. Liu T, Zhang L, Joo D, Sun SC. 2017; NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:17023. DOI: 10.1038/sigtrans.2017.23. PMID: 29158945. PMCID: PMC5661633.
Article
23. Műzes G, Molnár B, Tulassay Z, Sipos F. 2012; Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol. 18:5848–5861. DOI: 10.3748/wjg.v18.i41.5848. PMID: 23139600. PMCID: PMC3491591.
Article
24. Strober W, Fuss IJ. 2011; Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 140:1756–1767. DOI: 10.1053/j.gastro.2011.02.016. PMID: 21530742. PMCID: PMC3773507.
Article
25. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. 2017; The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017:3908061. DOI: 10.1155/2017/3908061. PMID: 28316374. PMCID: PMC5337858.
Article
26. Chamoun-Emanuelli AM, Bryan LK, Cohen ND, Tetrault TL, Szule JA, Barhoumi R, Whitfield-Cargile CM. 2019; NSAIDs disrupt intestinal homeostasis by suppressing macroautophagy in intestinal epithelial cells. Sci Rep. 9:14534. DOI: 10.1038/s41598-019-51067-2. PMID: 31601922. PMCID: PMC6787209.
Article
27. Song EM, Jung SA, Lee JS, Kim SE, Shim KN, Jung HK, Yoo K, Park HY. 2013; Benzoxazole derivative B-98 ameliorates dextran sulfate sodium-induced acute murine colitis and the change of T cell profiles in acute murine colitis model. Korean J Gastroenterol. 62:33–41. DOI: 10.4166/kjg.2013.62.1.33. PMID: 23954958.
Article
28. Yamada A, Arakaki R, Saito M, Tsunematsu T, Kudo Y, Ishimaru N. 2016; Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 22:2195–2205. DOI: 10.3748/wjg.v22.i7.2195. PMID: 26900284. PMCID: PMC4734996.
Article
29. Cătană CS, Berindan Neagoe I, Cozma V, Magdaş C, Tăbăran F, Dumitraşcu DL. 2015; Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 21:5823–5830. DOI: 10.3748/wjg.v21.i19.5823. PMID: 26019446. PMCID: PMC4438016.
Article
30. Lee SH, Kwon JE, Cho ML. 2018; Immunological pathogenesis of inflammatory bowel disease. Intest Res. 16:26–42. DOI: 10.5217/ir.2018.16.1.26. PMID: 29422795. PMCID: PMC5797268.
Article
Full Text Links
  • KJPP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr